Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Nicolas Jonckheere

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0496-0661; OpenAlex author ID A5028455629. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 6 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 18

  1. Targeted photodynamic therapy for pancreatic cancer: recent innovations from fundamentals to in vivo and clinical applications (2020-2025). Co-author DOI 10.1039/d5cc05629b↗
  2. The kinase domain of TRPM7 interacts with PAK1 and regulates pancreatic cancer cell epithelial-to-mesenchymal transition. Co-author DOI 10.1038/s41419-025-07665-2↗
  3. Identification of pancreatic adenocarcinoma immune subtype associated with tumor neoantigen from aberrant alternative splicing. Co-author DOI 10.21037/jgo-24-340↗
  4. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Co-author DOI 10.1111/boc.202100003↗
  5. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Co-author DOI 10.3390/cancers13225746↗
  6. Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers13246197↗
  7. Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival. Co-author DOI 10.3390/cancers12113309↗
  8. Fine-tuning autophagy in pancreatic adenocarcinoma: full blockage is required. Co-author DOI 10.21037/atm.2019.03.01↗
  9. TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Last author DOI 10.3390/cancers10080254↗
  10. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Co-author DOI 10.1016/j.critrevonc.2017.01.002↗
  11. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling … Last author DOI 10.1016/j.bbagrm.2015.10.014↗
  12. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2015.05.033↗
  13. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Co-author DOI 10.1016/j.bbrc.2014.12.025↗
  14. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Co-author DOI 10.1038/onc.2014.11↗
  15. Targeting MUC4 in pancreatic cancer: miRNAs. Co-author DOI 10.18632/oncoscience.249↗
  16. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-re… Last author DOI 10.18632/oncotarget.3414↗
  17. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Last author DOI 10.1038/onc.2012.179↗
  18. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. Co-author DOI 10.1371/journal.pone.0032232↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabelle VAN SEUNINGEN · 16 shared papers, 2012–2025 · strength 1.50
  2. Fatima Lahdaoui · 5 shared papers, 2015–2021 · strength 0.42
  3. Romain Vasseur · 5 shared papers, 2015–2021 · strength 0.41
  4. Audrey Vincent · 5 shared papers, 2015–2022 · strength 0.38
  5. Nicolas Skrypek · 6 shared papers, 2012–2021 · strength 0.37
  6. Julie Auwercx · 2 shared papers, 2020–2025 · strength 0.32
  7. Mathieu Gautier · 2 shared papers, 2020–2025 · strength 0.32
  8. Nihad Boukrout · 3 shared papers, 2018–2021 · strength 0.32
  9. Jérôme Torrisani · 3 shared papers, 2015–2021 · strength 0.23
  10. Elsa Hadj Bachir · 2 shared papers, 2020–2022 · strength 0.22
  11. Nicolas Stoup · 2 shared papers, 2021–2022 · strength 0.22
  12. Jiyong Liu · 1 shared paper, 2024 · strength 0.21
  13. Qiong Du · 1 shared paper, 2024 · strength 0.21
  14. Xianjun Yu · 1 shared paper, 2024 · strength 0.21
  15. Souleymane Sarr · 1 shared paper, 2026 · strength 0.21
  16. Nadira Delhem · 1 shared paper, 2026 · strength 0.21
  17. Gaël S. Roth · 1 shared paper, 2026 · strength 0.21
  18. Anne‐Laure Bulin · 1 shared paper, 2026 · strength 0.21
  19. Hélène Burckel · 1 shared paper, 2026 · strength 0.21
  20. Vincent Sol · 1 shared paper, 2026 · strength 0.21
  21. Solange Tréhoux · 2 shared papers, 2015 · strength 0.12
  22. Charles Poiraud · 1 shared paper, 2022 · strength 0.12
  23. Stéphanie Truant · 1 shared paper, 2022 · strength 0.12
  24. Pascal Pigny · 1 shared paper, 2022 · strength 0.12
  25. Yannick Delpu · 2 shared papers, 2015 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.